The pharmacological profile of tirzepatide includes once-weekly subcutaneous administration, with dose titration typically starting at 2.5 mg (an initiation dose for tolerability) and increasing gradually every 4 weeks through 5 mg, 7.5 mg, 10 mg, 12.5 mg to a maximum of 15 mg based on glycaemic response and tolerability
4 A new safety signal flagged in TRIUMPH-4 is dysaesthesia, an abnormal skin sensation that people describe as burning, tingling, or pins-and-needles
In these cases, the barrier is cellular efficiency and lipid metabolism
As noted in recent clinical reviews, nasal glucagon represents a significant advance in hypoglycemia rescue
The new tablets are cheaper than the shots, but theyre still not cheap
Two optical slices from the Z-stack in Fig